- Research Article
- 10.29011/2574-7754.101810
Novel Treatment for Parkinson’s Disease with Intravenous Allogeneic Pluripotent Non-Tumorigenic Adipose Stem Cell Transplantation: A Case Report
- May 20, 2024
- Annals of Case Reports
- Gregorio Chazenbalk + 5 more +5
The present study evaluates the safety and efficacy of allogeneic pluripotent non-tumorigenic adipose stem cells (PASCs) intravenously (IV) injected in a patient with classical Parkinson's disease. PASCs were isolated from lipoaspirate material; pluripotency, teratogenesis, chromosomal integrity, and purity were determined accordingly. The patient was injected intravenously with 3 doses of 25 x 10 6 PASCs over time (0, 3, 10 months), and safety and symptom improvements were assessed at 0, 3, 10, and 16 months using validated clinical measurements. The patient exhibited no adverse effects from the PASC transplantation over 16 months of treatment, with significant improvements in activities of daily living, motor function, fall risk, and balance. This case report demonstrates safety and significant improvements in critical clinical outcomes of intravenous allogenic pluripotent nontumorigenic PASC transplantation, making PASCs an excellent candidate for cell therapy in patients with PD.
Read more